Mariner LLC boosted its position in Grifols, S.A. (NASDAQ:GRFS - Free Report) by 382.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 119,472 shares of the biotechnology company's stock after acquiring an additional 94,706 shares during the period. Mariner LLC's holdings in Grifols were worth $889,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. R Squared Ltd bought a new position in shares of Grifols in the 4th quarter worth $28,000. GAMMA Investing LLC boosted its holdings in Grifols by 44.5% during the fourth quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company's stock worth $37,000 after buying an additional 1,527 shares during the last quarter. Blue Trust Inc. grew its position in shares of Grifols by 254.0% during the 4th quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company's stock worth $52,000 after buying an additional 4,970 shares during the period. Envestnet Portfolio Solutions Inc. bought a new stake in shares of Grifols in the 4th quarter valued at about $77,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of Grifols in the 4th quarter valued at approximately $91,000.
Analyst Upgrades and Downgrades
Separately, Morgan Stanley initiated coverage on shares of Grifols in a report on Wednesday, February 12th. They set an "overweight" rating for the company.
Read Our Latest Analysis on GRFS
Grifols Trading Up 4.7 %
Shares of GRFS traded up $0.33 during trading hours on Friday, reaching $7.35. The stock had a trading volume of 543,821 shares, compared to its average volume of 1,196,636. The firm has a 50-day moving average of $7.44 and a 200 day moving average of $7.70. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. The company has a market cap of $5.05 billion, a P/E ratio of 6.28 and a beta of 0.44. Grifols, S.A. has a 52 week low of $5.79 and a 52 week high of $9.96.
About Grifols
(
Free Report)
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
Recommended Stories
Before you consider Grifols, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grifols wasn't on the list.
While Grifols currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
